IMRN Immuron Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1660046 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: AUD | FY20252025-06-30 | FY20242024-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | 7.29M | 4.90M |
| Cost of revenue | 2.52M | 1.57M |
| Gross profit | 4.77M | 3.34M |
| R&D expense | 3.60M | 5.38M |
| SG&A expense | 4.48M | 4.56M |
| Operating income | -5.34M | -5.80M |
| Interest expense | 7,305 | 7,576 |
| Pretax income | -5.22M | -6.94M |
| Net income | -5.22M | -6.94M |
| EBITDA | -5.29M | -5.76M |
| EPS (basic) | -2.26 | -3.04 |
| EPS (diluted) | -2.26 | -3.04 |
| Weighted avg. shares (diluted) | 230.94M | 227.86M |
| Balance sheet | ||
| Cash & equivalents | 2.83M | 11.66M |
| Receivables | 1.93M | 1.39M |
| Inventory | 1.77M | 1.58M |
| Current assets | 10.02M | 14.73M |
| PP&E, netmay include right-of-use assets (IFRS) | 113,950 | 154,347 |
| Total assets | 10.13M | 15.55M |
| Current liabilities | 1.97M | 2.70M |
| Total liabilities | 2.06M | 2.84M |
| Shareholders' equity | 8.07M | 12.71M |
| Cash flow statement | ||
| Operating cash flow | -6.14M | -5.88M |
| Capital expenditure | — | 195 |
| Free cash flow | — | -5.88M |
| Investing cash flow | -2.90M | 327,561 |
| Financing cash flow | 199,747 | 829 |
| Depreciation & amortization | 49,688 | 45,981 |
| Stock-based compensation | 304,243 | 3,299 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.